It’s been a tough time for equity investors, but the big names that everyone flocks to when they need to sell stock in a proper share offering are spoiled for choice.
So much so, that amid all the rights issues and other primary deals that – owing to new regulatory relaxation – no longer need pre-emptive rights, fatigue is setting in.
There is plenty of grumbling that companies are being woefully optimistic about the kind of investment case they need to put forward.
Access intelligence that drives action
To unlock this research, enter your email to log in or enquire about access
